Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Acq. announced
CC transcript
Shire plc (SHPG) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/01/2018 8-K Quarterly results
Docs: "Shire Delivers Product Sales Growth of 6% and Continues to Execute Against Key Priorities in Q3 2018 Delivered product sales of $3.8 billion; growth driven by Immunology, recently-launched products, and international expansion Received U.S. Food and Drug Administration and Health Canada approval for TAKHZYRO and launched in the U.S. Accelerated debt pay-down through proceeds from the $2.4 billion sale of the Oncology franchise and strong net operating cash flow – Shire plc , the leading global biotech company focused on rare diseases, announces unaudited results for the three months ended September 30, 2018. Flemming Ornskov, M.D., M.P.H., Shire Chief Executive Officer, commented: “We continue to deliver solid growth and pay down our debt while advancing our late-stage pipeline. Our focus ..."
07/31/2018 8-K Quarterly results
Docs: "Shire Delivers Q2 2018 Product Sales Growth of 6% and Continued Regulatory and Pipeline Progress Product sales grew to $3.8 billion driven by Immunology, recently launched products, and international expansion Innovative pipeline continued to advance with 7 programs in registration and 16 in Phase 3 U.S. Food and Drug Administration approval received for state-of-the-art plasma manufacturing facility $0.9 billion in net operating cash flow enabled continued debt pay-down – Shire plc , the leading global biotech company focused on rare diseases, announces unaudited results for the three months ended June 30, 2018. Flemming Ornskov, M.D., M.P.H., Shire Chief Executive Officer, commented: “Shire continued to deliver on its key priorities of commercial execution, pipeline advancement, debt pay..."
04/26/2018 8-K Quarterly results
Docs: "Shire Delivers 7% Product Sales Growth and Robust Pipeline Progress in Q1 2018 Growth driven by Immunology, recently-launched products, and international expansion Innovative pipeline progresses with 15 programs in Phase 3 and 7 programs in registration including lanadelumab Delivers Non GAAP diluted earnings per ADS of $3.86, up 6% year-on-year; GAAP diluted earnings per ADS were $1.81, up 47% $1.0 billion in net operating cash flow enabled continued debt pay down"
10/27/2017 8-K Quarterly results
Docs: "Shire reports strong earnings growth in Q3 2017; reiterates full year guidance"
08/03/2017 8-K Quarterly results
Docs: "Shire reports strong Q2 2017 operating results and cash flow; updates full year guidance"
05/02/2017 8-K Form 8-K - Current report
11/01/2016 8-K Form 8-K - Current report
08/02/2016 8-K Form 8-K - Current report
04/29/2016 8-K Quarterly results
Docs: "– Shire plc announces unaudited results for the three months ended March 31, 2016. Financial Highlights Q1 2016 Growth Non GAAP CER Product sales $1,627 million +14% +16% Total revenues $1,709 million +15% +17% Non GAAP operating income $797 million +17% +16% US GAAP operating income from continuing operations $544 million +15% Non GAAP EBITDA margin 46% 0pps US GAAP net income margin 25% -3pps Non GAAP net income $632 million +13% US GAAP net income $419 million +2% Non GAAP diluted earnings per ADS $3.19 +12% +12% US GAAP diluted earnings per ADS $2.12 +2% Non GAAP cash generation $492 million -5% Non GAAP free cash flow $338 million -38% US GAAP net cash provided by operating activities $390 million -31% Percentages compare to equivalent 2015 period. On a Constant Exchange Rate basis,..."
10/24/2013 8-K Quarterly results
Docs: "www.shire.com Strong third quarter and increased Non GAAP earnings expectations October 24, 2013 – Shire announces results for the three months to September 30, 2013."
05/02/2013 8-K Quarterly results
Docs: "www.shire.com New Chief Executive reports Q1 results and sets out strategy for growth Shire delivers 10% increase in Non GAAP earnings; full year EPS guidance in line with consensus May 2, 2013 – Shire announces results for the three months to March 31, 2013."
10/25/2012 8-K Quarterly results
Docs: "www.shire.com Shire on Track for Double Digit Full Year Earnings Growth Advancing Late Stage Pipeline of new Growth Opportunities October 25, 2012 – Shire announces results for the three months to September 30, 2012."
08/01/2012 8-K Quarterly results
Docs: "SHIRE SECOND QUARTER PRODUCT SALES UP 16% ON TRACK TO DELIVER DOUBLE DIGIT FULL YEAR EARNINGS GROWTH"
04/26/2012 8-K Quarterly results
Docs: "Shire delivers strong first quarter performance and reiterates its expectation of good full year earnings growth. April 26, 2012 – Shire plc , the global specialty biopharmaceutical company, announces results for the three months to March 31, 2012."
10/28/2011 8-K Quarterly results
Docs: "www.shire.com Continued strong product sales performance in Q3: On track to deliver significant 2011 earnings growth October 28, 2011 – Shire plc , the global specialty biopharmaceutical company, announces results for the three months to September 30, 2011."
07/28/2011 8-K Quarterly results
Docs: "www.shire.com Shire’s quarterly revenues grow by 25% to $1 billion for the first time July 28, 2011 – Shire plc , the global specialty biopharmaceutical company, announces results for the three months to June 30, 2011."
04/28/2011 8-K Form 8-K - Current report
10/29/2010 8-K Quarterly results
Docs: "www.shire.com Continued excellent performance in Q3. Full year earnings expectations increased. New value in pipeline emerging. October 29, 2010 – Shire plc the global specialty biopharmaceutical company, announces results for the three months to September 30, 2010."
08/04/2010 8-K Quarterly results
Docs: "Shire delivers excellent Q2 performance with total revenues up 35%. Full year earnings expectations raised. August 4, 2010 – Shire plc the global specialty biopharmaceutical company, announces results for the three months to June 30, 2010."
04/29/2010 8-K Quarterly results
Docs: "www.shire.com Shire’s replenished portfolio drives excellent quarterly performance April 29, 2010 – Shire plc the global specialty biopharmaceutical company, announces results for the three months to March 31, 2010."
11/04/2004 8-K Quarterly results
Docs: "12 noon BST 7am EDT"
07/31/2003 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"SHIRE PHARMACEUTICALS GROUP PLC HAMPSHIRE INTERNATIONAL BUSINESS PARK, CHINEHAM, BASINGSTOKE RG24 8EP UK TEL"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy